Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003

Journal of Clinical Oncology

Volumn 25, Issue 15, 2007, Pages 1993-1999

  Kristinsson, Sigurdur Yngvi ^a   Landgren, Ola ^a   Dickman, Paul W ^a   Derolf, Åsa Rangert ^a   Björkholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; POPULATION RESEARCH; PRIORITY JOURNAL; SWEDEN; TREATMENT RESPONSE; AGE DISTRIBUTION; AUTOTRANSPLANTATION; COHORT ANALYSIS; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SWEDEN; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34249945940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.0100     Document Type: Article

References (58)

1. Kyle RA, Rajkumar SV: Plasma cell disorders, in Goldman L, Ausiello DA (eds): Cecil Textbook of Medicine (ed 22). Philadelphia, PA, WB Saunders, 2004, pp 1184-1195
2. National Board of Health and Welfare, Centre for Epidemiology, Cancer Incidence in Sweden 2001: Official Statistics of Sweden. Stockholm, Sweden, National Board of Health and Welfare, Centre for Epidemiology, 2003
3. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2000. Bethesda, MD, National Cancer Institute, 2003
4. Salmon SE, Cassady JR: Plasma cell neoplasms, in de Vita VT, Hellman S, Rosenberg SA (eds): Cancer (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 2344-2375
5. Osgood EE: The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 9:1-10, 1960
6. Alexanian R, Haut A, Khan AU, et al: Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685, 1969
7. Bergsagel DE, Sprague CC, Austin C, et al: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 21:87-99, 1962
8. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials - Myeloma Trialists' Collaborative Group. J Clin Oncol 16:3832-3842, 1998
9. Mellstedt H, Aahre A, Bjorkholm M, et al: Interferon therapy in myelomatosis. Lancet 1:245-247, 1979
10. Myeloma Trialist's Collaborative Group: Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020-1034, 2001
11. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822-824, 1983
12. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984
13. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
14. Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study - Nordic Myeloma Study Group. Blood 95:7-11, 2000
15. Barlogie B, Hall R, Zander A, et al: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298-1301, 1986
16. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
17. Fermand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227-9233, 2005
18. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-936, 2006
19. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
20. Gahrton G, Svensson H, Cavo M, et al: Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113:209-216, 2001
21. Lokhorst HM, Segeren CM, Verdonck LF, et al: Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 21:1728-1733, 2003
22. Juliusson G, Celsing F, Turesson I, et al: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96, 2000
23. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
24. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
25. Jagannath S, Durie BG, Wolf J, et al: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783, 2005
26. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
27. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
28. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
29. Mattsson B, Wallgren A: Completeness of the Swedish Cancer Register: Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 23:305-313, 1984
30. Henson DE, Ries LA: The relative survival rate. Cancer 76:1687-1688, 1995
31. Dickman PW, Adami HO: Interpreting trends in cancer patient survival. J Intern Med 260:103-117, 2006
32. Hakulinen T: Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38:933-942, 1982
33. Dickman PW, Sloggett A, Hills M, et al: Regression models for relative survival. Stat Med 23:51-64, 2004
34. Turesson I, Abildgaard N, Ahlgren T, et al: Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors. Br J Haematol 106:1005-1012, 1999
35. Lenhoff S, Hjorth M, Westin J, et al: Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol 133:389-396, 2006
36. Lundin J, Osterborg A, Bjorkholm M, et al: Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III. Hematol J 4:248-252, 2003
37. Johnsen HE, Bjorkstrand B, Carlson K, et al: Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. Leuk Lymphoma 24:81-91, 1996
38. Ohrling M, Bjorkholm M, Osterborg A, et al: Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma. Eur J Haematol 51:45-49, 1993
39. Osterborg A, Ahre A, Bjorkholm M, et al: Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III: A randomized study from MGCS. Eur J Haematol 43:54-62, 1989
40. Mellstedt H, Osterborg A, Bjorkholm M, et al: Induction treatment with alpha-interferon in multiple myeloma: An interim report from MGCS. Eur J Haematol Suppl 51:124-128, 1989
41. Ahre A, Bjorkholm M, Osterborg A, et al: High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma: A pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 41:123-130, 1988
42. Ahre A, Bjorkholm M, Mellstedt H, et al: Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: A randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 68:1331-1338, 1984
43. Ahre A, Bjorkholm M, Mellstedt H, et al: Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. Eur J Cancer Clin Oncol 19:499-506, 1983
44. Mellstedt H, Bjorkholm M, Holm G: Intermittent melphalan and prednisolone therapy in plasma cell myeloma. Acta Med Scand 202:5-9, 1977
45. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
46. Augustson BM, Begum G, Dunn JA, et al: Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23:9219-9226, 2005
47. Anagnostopoulos A, Gika D, Symeonidis A, et al: Multiple myeloma in elderly patients: Prognostic factors and outcome. Eur J Haematol 75:370-375, 2005
48. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon, France, IARC Press, 2004
49. Berger U, Maywald O, Pfirrmann M, et al: Gender aspects in chronic myeloid leukemia: Long-term results from randomized studies. Leukemia 19:984-989, 2005
50. Provencio M, Espana P, Millan I, et al: Prognostic factors in Hodgkin's disease. Leuk Lymphoma 45:1133-1139, 2004
51. Landgren O, Zhang Y, Zahm SH, et al: Risk of multiple myeloma following medication use and medical conditions: A case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15:2342-2347, 2006
52. Wang LH, Yang XY, Mihalic K, et al: Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem 276:31839-31844, 2001
53. Selby P, Gillis C, Haward R: Benefits from specialised cancer care. Lancet 348:313-318, 1996
54. Stiller CA: Centralisation of treatment and survival rates for cancer. Arch Dis Child 63:23-30, 1988
55. Stiller CA: Centralised treatment, entry to trials and survival. Br J Cancer 70:352-362, 1994
56. Stiller CA, Draper GJ: Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child 64:657-661, 1989
57. Lenhard RE Jr, Enterline JP, Crowley J, et al: The effects of distance from primary treatment centers on survival among patients with multiple myeloma. J Clin Oncol 5:1640-1645, 1987
58. Hjorth M, Holmberg E, Rodjer S, et al: Patient accrual and quality of participation in a multicentre study on myeloma: A comparison between major and minor participating centres. Br J Haematol 91:109-115, 1995